Modality
ADC
MOA
CD47i
Target
DLL3
Pathway
Checkpoint
DMDHemophilia A
Development Pipeline
Preclinical
Mar 2019
→ Mar 2030
PreclinicalCurrent
NCT04907615
126 pts·Hemophilia A
2019-03→2030-03·Completed
126 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-03-144.0y awayInterim· Hemophilia A
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Preclinical
Complet…
Catalysts
Interim
2030-03-14 · 4.0y away
Hemophilia A
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04907615 | Preclinical | Hemophilia A | Completed | 126 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ARG-1924 | Argenx | Preclinical | DLL3 |